Recent

% | $
Quotes you view appear here for quick access.

Seattle Genetics, Inc. Message Board

  • richardryan40 richardryan40 Mar 27, 2012 3:09 AM Flag

    2012 ADCETRIS Calendar

    ADCETRIS is being evaluated in:
    1. A phase III clinical trial (the AETHERA trial) for patients at high risk of residual Hodgkin lymphoma following autologous stem cell transplant (ASCT)
    2. A phase II trial for relapsed or refractory CD30-positive non-Hodgkin lymphomas
    3. A phase II trial for CD30-positive non-lymphoma malignancies
    4. A phase II retreatment trial for relapsed patients who previously responded to ADCETRIS
    5. A phase I trial in combination with multi-agent chemotherapy for front-line treatment of Hodgkin lymphoma
    6. A phase I trial in combination with multi-agent chemotherapy for front-line treatment of mature T-cell lymphomas. 7.A trial in CD30-positive cutaneous T-cell lymphomas to begin in mid-2012
    8. A front-line trial in Hodgkin lymphoma to begin by late 2012 or early 2013
    9. A front-line trial in mature T-cell lymphomas. to begin by late 2012 or early 2013

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
SGEN
45.30+1.32(+3.00%)Aug 26 4:00 PMEDT